Self-reported chemotherapy-related cognitive impairment compared with cognitive complaints following menopause.

ABSTRACT:

Objective

Cancer-related cognitive impairment (CRCI) is commonly reported following the administration of cancer treatment. Current longitudinal studies, primarily in women with breast cancer, suggest that up to 35% to 60% of patients exhibit persistent CRCI (pCRCI) following completion of chemotherapy. Complaints of subjective cognitive decline (SCD) are also commonly reported by women during and following the menopause transition in noncancer patients. Although the majority of evidence for cognitive difficulties in cancer patients and survivors is attributed to chemotherapy, there is growing evidence to suggest that menopausal status can also influence cognitive function in cancer patients.

Methods

Given that menopausal status may be contributing to pCRCI, we compared a gr

SUBMITTER: Vega JN 

PROVIDER: S-EPMC6993087 | biostudies-literature | 2018 Sep

REPOSITORIES: biostudies-literature